1. Home
  2. SG vs SGMT Comparison

SG vs SGMT Comparison

Compare SG & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sweetgreen Inc.

SG

Sweetgreen Inc.

SELL

Current Price

$10.08

Market Cap

641.7M

ML Signal

SELL

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$8.00

Market Cap

648.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SG
SGMT
Founded
2007
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
641.7M
648.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SG
SGMT
Price
$10.08
$8.00
Analyst Decision
Buy
Buy
Analyst Count
14
12
Target Price
$8.08
★ $27.91
AVG Volume (30 Days)
★ 4.7M
1.4M
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.82
N/A
Revenue
★ $679,474,000.00
$2,000,000.00
Revenue This Year
$0.63
N/A
Revenue Next Year
$7.98
N/A
P/E Ratio
$12.93
★ N/A
Revenue Growth
★ 0.39
N/A
52 Week Low
$4.49
$4.50
52 Week High
$10.64
$11.45

Technical Indicators

Market Signals
Indicator
SG
SGMT
Relative Strength Index (RSI) 72.05 37.31
Support Level $6.24 $6.21
Resistance Level $10.63 $11.33
Average True Range (ATR) 0.39 0.56
MACD 0.09 -0.14
Stochastic Oscillator 72.11 16.37

Price Performance

Historical Comparison
SG
SGMT

About SG Sweetgreen Inc.

Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing. Its menu involves, Kids' meal, salads, sides, local items, Protein Plates, Desserts, Drinks and Others.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: